ID: ALA3884960

Max Phase: Preclinical

Molecular Formula: C24H25ClN6O2

Molecular Weight: 464.96

Molecule Type: Small molecule

Representations

Canonical SMILES:  C=CC(=O)Nc1ccccc1Oc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1Cl

Standard InChI:  InChI=1S/C24H25ClN6O2/c1-3-22(32)28-20-6-4-5-7-21(20)33-23-19(25)16-26-24(29-23)27-17-8-10-18(11-9-17)31-14-12-30(2)13-15-31/h3-11,16H,1,12-15H2,2H3,(H,28,32)(H,26,27,29)

Standard InChI Key:  WOQNVLPDIGPVKR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 464.96

Molecular Weight (Monoisotopic): 464.1728

AlogP: 4.54

#Rotatable Bonds: 7

Polar Surface Area: 82.62

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.62

CX Basic pKa: 7.96

CX LogP: 4.82

CX LogD: 4.15

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.50

Np Likeness Score: -1.52

References

1. Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS, Ficarro SB, Mowafy S, Tam CP, Rao S, Du G, Griffin JD, Sorger PK, Marto JA, Westover KD, Gray NS..  (2017)  Structure-guided development of covalent TAK1 inhibitors.,  25  (3): [PMID:28011204] [10.1016/j.bmc.2016.11.035]

2. Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G, Nonami A, Griffin JD, Lauffenburger DA, Westover KD, Sorger PK, Gray NS..  (2017)  Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.,  25  (4): [PMID:28038940] [10.1016/j.bmc.2016.11.034]

Source

Source(1):

• Scientific Literature